"Doctor, Would You Prescribe a Pill to Help Me...?" A National Survey of Physicians on Using Medicine for Human Enhancement

American Journal of Bioethics

Volumn 11, Issue 1, 2011, Pages 3-13

  Hotze, Timothy D ^a   Shah, Kavita ^b   Anderson, Emily E ^a,c   Wynia, Matthew K ^a,d  

^a AMERICAN MEDICAL ASSOCIATION   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

biotechnology; enhancement; physician survey; prescribing behavior

Indexed keywords

NOOTROPIC AGENT; PERFORMANCE ENHANCING SUBSTANCE; PRESCRIPTION DRUG;

ARTICLE; ECONOMICS; ETHICS; FEMALE; HEALTH CARE DELIVERY; HEALTH INSURANCE; HEALTH PERSONNEL ATTITUDE; HUMAN; MALE; MEDICAL TECHNOLOGY; MIDDLE AGED; PHYSICIAN; PRESCRIPTION; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; SAFETY; SOCIOECONOMICS; STANDARD; STATISTICS; UNITED STATES;

ATTITUDE OF HEALTH PERSONNEL; BIOMEDICAL ENHANCEMENT; DRUG PRESCRIPTIONS; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; INSURANCE, HEALTH; MALE; MIDDLE AGED; NOOTROPIC AGENTS; PERFORMANCE-ENHANCING SUBSTANCES; PHYSICIANS; PRESCRIPTION DRUGS; QUESTIONNAIRES; SAFETY; SOCIOECONOMIC FACTORS; UNITED STATES;

EID: 79952468722     PISSN: 15265161     EISSN: 15360075     Source Type: Journal    
DOI: 10.1080/15265161.2011.534957     Document Type: Article

References (42)

1. American Academy of Pediatrics Committee on Sports Medicine and Fitness. 2005. Policy statement on use of performance enhancing substances. Pediatrics, 115(4): 1103-1106.
2. American College of Sports Medicine. 1984. Position stand: The use of anabolic-androgenic steroids in sports. Medicine and Science in Sport and Exercise, Available at: http://www.acsm-msse.org/pt/pt-core/template-journal/msse/media/0587.pdf
3. American College of Sports Medicine. 1996. Position stand: The use of blood doping as an ergogenic aid. Medicine and Science in Sport and Exercise, Available at: http://www.acsm-msse.org/pt/pt-core/template-journal/msse/media/0696a.pdf
4. American Medical Association. 1998a. Health policies of the House of Delegates. H-320.953. Definition of screening and medical necessity, Chicago: American Medical Association.
5. American Medical Association. 1995a. Health policies of the house of delegates. H-470.978. Blood doping, Chicago: American Medical Association.
6. American Medical Association. 1995b. Health policies of the house of delegates. H-470.976. Abuse of Anabolic Steroids, Chicago: American Medical Association.
7. American Medical Association. 1999b. Health policies of the house of delegates. H-475.992. Definitions of "cosmetic" and "reconstructive" surgery, Chicago: American Medical Association.
8. American Medical Association. 2010. Physician characteristics and distribution in the US, 2010 ed., Chicago: American Medical Association.
9. American Medical Association Council on Ethical and Judicial Affairs. 1986. Code of medical ethics. Opinion E-4.04. Economic incentives and levels of care, Chicago: American Medical Association.
10. American Medical Association Council on Ethical and Judicial Affairs. 1996. Code of medical ethics: Opinion E-2.11: Gene therapy, Chicago: American Medical Association.
11. American Medical Association Council on Ethical and Judicial Affairs. 1998b. Code of medical ethics. Opinion E-8.20: Invalid medical treatment, Chicago: American Medical Association.
12. American Medical Association Council on Ethical and Judicial Affairs. 1999a. Code of medical ethics. Opinion E-2.147. Cloning to produce children, Chicago: American Medical Association.
13. American Medical Association Council on Ethical and Judicial Affairs. 2002. Code of medical ethics. Opinion E-8.06: Prescribing and dispensing drugs and devices, Chicago: American Medical Association.
14. American Medical Association Council on Ethical and Judicial Affairs. 2003. Code of medical ethics. Opinion E-2.19: Unnecessary medical services, Chicago: American Medical Association.
15. American Medical Association Council on Ethical and Judicial Affairs. 2007. Report: Enhancement: Distinguishing between therapeutic and non-therapeutic uses of medicine, Chicago: American Medical Association.
16. Asch, D. A., Jedrziewski, M. K. and Christakis, N. A. 1997. Response rates to mail surveys published in medical journals. Journal of Clinical Epidemiology, 50(10): 1129-1136.
17. Bergstrom, L. S. and Lynoe, N. 2008. Enhancing concentration, mood and memory in healthy individuals: An empirical study of attitudes among general practitioners and the general population. Scandinavian Journal of Public Health, 36: 532-537.
18. Bruce, D. 2006. Ethical and social issues in nanobiotechnologies. EMBO Reports, 7(8): 754-758.
19. Committee on Drugs and Committee on Bioethics, American Academy of Pediatrics. 1997. Considerations related to the use of recombinant human growth hormone in children. Pediatrics, 99: 122-129.
20. Davis, K. 1995. Reshaping the female body: The dilemma of cosmetic surgery, New York: Routledge.
21. Dillman, D. A. 1991. The design and administration of mail surveys. Annual Review of Sociology, 17: 225-249.
22. Gillett, G. 2006. Cyborgs and moral identity. Journal of Medical Ethics, 32: 79-83.
23. Hanson, M. J. and Callahan, D. 1999. "The goals of medicine: Setting new priorities". In The goals of medicine: The forgotten issues in health care reform, Edited by: Hanson, M. J. and Callahan, D. 1-54. Washington, DC: Georgetown University Press.
24. Henry, M., Fishman, J. and Youngner, S. 2007. Propranolol and the prevention of post-traumatic stress disorder: Is it wrong to erase the "sting" of bad memories?. American Journal of Bioethics, 7(9): 12-20.
25. Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D. and Schaff, H. V. 1997. Valvular heart disease associated with fenfluramine-phentermine. New England Journal of Medicine, 337: 581-588.
26. Juengst, E. 1998. "What does enhancement mean?". In Enhancing human traits: Ethical and social implications, Edited by: Parens, E. 29-47. Washington, DC: Georgetown University Press.
27. Kamm, F. M. 2005. Is there a problem with enhancement?. American Journal of Bioethics, 5(3): 5-14.
28. Kramer, P. D. 1993. Listening to Prozac, New York: Viking.
29. Miller, F. G., Brody, H. and Chung, K. C. 2000. Cosmetic surgery and the internal morality of medicine. Cambridge Quarterly of Healthcare Ethics, 9: 353-364.
30. Miller, P. and Wilsdon, J. 2006. "Stronger, longer, smarter, faster". In Better humans? The politics of human enhancement and life extension Edited by: Miller, P. and Wilsdon, J. 13-27. Available at: http://www.demos.co.uk/projects/currentprojects/betterhumans
31. National Nanotechnology Initiative. 2006. Responsible development and international cooperation Available at: http://www.nano.gov/html/society/Responsible_Development.htm
32. Parens, E. 1998. "Is better always good? The enhancement project". In Enhancing human traits: Ethical and social implications, Edited by: Parens, E. 1-28. Washington, DC: Georgetown University Press.
33. President's Council on Bioethics. 2003. Beyond therapy: Biotechnology and the pursuit of happiness, New York: ReganBooks.
34. President's Council on Bioethics. 2008. Human dignity and bioethics: Essays commissioned by the President's Council on Bioethics, Washington, DC: President's Council on Bioethics. Available at: http://bioethics.georgetown.edu/pcbe/reports/human_dignity (accessed September 9, 2010)
35. Reynolds, G. 2007. Outlaw DNA. Play Magazine, New York Times,: 18-20. June
36. Rothman, S. M. and Rothman, D. J. 2003. The pursuit of perfection: The promise and perils of medical enhancement., New York: Pantheon Books.
37. Sade, R. 1998. Enhancement technology, ethics, and public policy. Journal of the South Carolina Medical Association, 94(9): 411-415.
38. Savulescu, J. 2005. New breeds of humans: The moral obligation to enhance. Ethics, Law and Moral Philosophy of Reproductive Biomedicine, 1(1): 36-39.
39. Smith, T. W. 2003. A review of methods to estimate the status of cases with unknown eligibility, Lenexa, KS: Report prepared for the American Association for Public Opinion Research (AAPOR) Standard Definitions Committee.
40. Stock, G. and Campbell, J., eds. 2000. Engineering the human germline: An exploration of the science and ethics of altering the genes we pass to our children, New York: Oxford University Press.
41. Walters, L. and Palmer, J. G. 1997. The ethics of human gene therapy, New York: Oxford University Press.
42. World Anti-Doping Agency. 2003. World Anti-Doping Code Available at: http://www.wada-ama.org/rtecontent/document/code_v3.pdf